|
Market Closed -
Xetra
09:17:34 07/09/26 pm AEST
|
After hours 01:44:23 am | |||
| 13.60 EUR | -3.41% |
|
13.57 | -0.22% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
Company Valuation: GENFIT
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 214.6 | 197 | 176 | 176.3 | 262.2 | 689.3 | - | - |
| Change | - | -8.19% | -10.69% | 0.17% | 48.73% | 162.93% | - | - |
| Enterprise Value (EV) 1 | 30.1 | 131.8 | 168.4 | 156.6 | 166.7 | 638.2 | 623.2 | 656.1 |
| Change | - | 337.75% | 27.79% | -6.98% | 6.41% | 282.97% | -2.36% | 5.29% |
| P/E | 3.51x | -8.27x | -6.1x | 118x | -3.06x | 35.6x | 91.5x | 12.6x |
| PBR | 2.55x | - | 2.59x | 2.54x | - | 8.76x | 10.5x | -56.1x |
| PEG | - | 0x | -0.3x | -1x | 0x | -0x | -1.5x | 0x |
| Capitalization / Revenue | 2.51x | 7.42x | 4.61x | 2.48x | 3.69x | 6.88x | 5.56x | 4.67x |
| EV / Revenue | 0.35x | 4.96x | 4.41x | 2.21x | 2.34x | 6.37x | 5.02x | 4.45x |
| EV / EBITDA | 0.87x | -5.18x | -6.75x | 31.3x | -3.22x | 22.7x | 10.3x | 9.09x |
| EV / EBIT | 0.95x | -4.83x | -6.33x | 47.7x | -37x | 18.7x | 9.3x | 7.72x |
| EV / FCF | 0.3x | - | -3.02x | 10.7x | -6.04x | 32.1x | 61.4x | 15.5x |
| FCF Yield | 330% | - | -33.2% | 9.35% | -16.6% | 3.12% | 1.63% | 6.44% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.23 | -0.48 | -0.58 | 0.03 | -1.72 | 0.3876 | 0.1506 | 1.098 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 85.58 | 26.57 | 38.18 | 70.94 | 71.12 | 100.2 | 124 | 147.5 |
| EBITDA 1 | 34.56 | -25.46 | -24.93 | 5.005 | -51.79 | 28.08 | 60.67 | 72.14 |
| EBIT 1 | 31.82 | -27.29 | -26.58 | 3.281 | -4.5 | 34.22 | 66.98 | 84.94 |
| Net income 1 | 67.26 | -23.72 | -28.89 | 1.507 | -85.97 | 22.88 | 6.8 | 33.27 |
| Net Debt 1 | -184.5 | -65.28 | -7.611 | -19.66 | -95.52 | -51.12 | -66.17 | -33.21 |
| Reference price 2 | 4.32 | 3.97 | 3.54 | 3.54 | 5.26 | 13.78 | 13.78 | 13.78 |
| Nbr of stocks (in thousands) | 49,727 | 49,655 | 49,712 | 49,865 | 49,795 | 50,024 | - | - |
| Announcement Date | 7/4/22 | 13/4/23 | 4/4/24 | 24/4/25 | 2/4/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.15x | 5.95x | 17.82x | 0.98% | 48.93B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.41x | 29.72x | -.--% | 40.73B | |
| 28.42x | 8.6x | 21.8x | 0.4% | 33.52B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 24.24x | 2.11x | 9.11x | 1.11% | 14.67B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 32.07x | 35.07x | 13.80x | 0.31% | 32.15B | |
| Weighted average by Cap. | 27.26x | 47.36x | 12.31x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
- Valuation GENFIT
Select your edition
All financial news and data tailored to specific country editions
